Estimation of cardiotoxicity of epirubicin-cisplatin by determination of myoglobin.
Serum myoglobin was determined in 29 patients during a total of 46 cycles of treatment with epirubicin-cisplatin. Statistical evaluation showed highly significant correlations between the myoglobin values and the age of the patients and the cumulative dose of the cytostatic agents applied.